BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23062817)

  • 1. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.
    Pal SK; Yamzon J; Sun V; Carmichael C; Saikia J; Ferrell B; Frankel P; Hsu J; Twardowski P; Stein CA; Margolin K
    Clin Genitourin Cancer; 2013 Jun; 11(2):121-7. PubMed ID: 23062817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
    Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
    Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience.
    Yildiran Keskin GS; Erturk I; Aykan MB; Acar R; Dumludag A; Topal A; Koseoglu C; Kuzu OF; Ornek E; Karadurmus N
    Oncol Res Treat; 2024; 47(6):262-272. PubMed ID: 38583428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
    Connolly EA; Weickhardt A; Grimison P; Asher R; Heller GZ; Lewin J; Liow E; Toner G; Tung ILY; Tran B; Hill S; Walpole E; McKenzie J; Kuchel A; Goh J; Forgeson G; Tan A; Joshi A; Wickham A; Tan H; Wang Y; Winstanley MA; Hamad N; Wong V
    BJU Int; 2022 Jun; 130 Suppl 1():5-16. PubMed ID: 35355402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
    Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
    J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
    Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
    Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
    Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
    Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
    J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study.
    Ferhatoglu F; Paksoy N; Khanmammadov N; Yildiz A; Ahmed MA; Gülbas Z; Basaran M
    Medicine (Baltimore); 2024 Feb; 103(8):e37213. PubMed ID: 38394499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.
    Feldman DR; Glezerman I; Patil S; Van Alstine L; Bajorin DF; Fischer P; Hughes A; Sheinfeld J; Bains M; Reich L; Woo K; Giralt S; Bosl GJ; Motzer RJ
    Clin Genitourin Cancer; 2015 Oct; 13(5):453-60. PubMed ID: 26072101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
    Lotz JP; Bui B; Gomez F; Théodore C; Caty A; Fizazi K; Gravis G; Delva R; Peny J; Viens P; Duclos B; De Revel T; Curé H; Gligorov J; Guillemaut S; Ségura C; Provent S; Droz JP; Culine S; Biron P;
    Ann Oncol; 2005 Mar; 16(3):411-8. PubMed ID: 15659420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
    Chevreau C; Massard C; Flechon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Fizazi K; Mourey L; Paci A; Guitton J; Thomas F; Lelièvre B; Ciccolini J; Moeung S; Gallois Y; Olivier P; Culine S; Filleron T; Chatelut E
    Cancer Med; 2021 Apr; 10(7):2250-2258. PubMed ID: 33675184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
    Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W
    Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report.
    Sokolova A; Chan O; Ullah W; Hamdani AA; Anwer F
    J Med Case Rep; 2017 Apr; 11(1):100. PubMed ID: 28395668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
    Kondagunta GV; Bacik J; Sheinfeld J; Bajorin D; Bains M; Reich L; Deluca J; Budnick A; Ishill N; Mazumdar M; Bosl GJ; Motzer RJ
    J Clin Oncol; 2007 Jan; 25(1):85-90. PubMed ID: 17194908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy with autologous stem cell transplantation for patients with extracranial germ cell tumors - experience of two Brazilian pediatric centers.
    Villela NC; Seber A; Macedo CRPD; Zecchin VG; Guimarães RFDC; Faria TMV; Vidal DO; Jorge GEM; Navarro G; Lopes LF
    Pediatr Hematol Oncol; 2023; 40(6):539-553. PubMed ID: 36940088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Mulherin BP; Brames MJ; Einhorn LH
    Am J Clin Oncol; 2015 Aug; 38(4):373-6. PubMed ID: 26214082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
    Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
    J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.